1. Pink Sheet
  2. >>Geography
  3. >>International

WHO Issues Environmental Sustainability Call To Regulators And Pharmaceutical Industry

 
• By Anabel Costa-Ferreira

The World Health Organization (WHO) has launched an initiative to highlight the pressing global need to reduce the impact of the pharmaceutical industry on the environment while maintaining high standards of safety and efficacy for products.

(Shutterstock)
Key Takeaways
  • Proposals set out in a call to action issued by the World Health Organization to improve sustainability in the pharmaceutical address all stages of the regulatory cycle from manufacturing to distribution.
  • The call to action will lead to a comprehensive white paper that will inform discussions at the COP30 in November 2025.
  • The pharmaceutical industry recognizes the need to improve environmental sustainability and is calling for convergence and collaboration among regulators and companies to tackle the issue.  

Global efforts to develop and adopt innovative regulatory practices to reduce the environmental impact of medicines have picked up pace after the World Health Organization (WHO) issued a call to...

Meanwhile, because of the complex and highly regulated nature of pharmaceutical products, the pharmaceutical industry has recognized the need for “a high degree of coordination and collaboration between industry, governments,...

More from International

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.

Quotable: Top Experts On Policy Hot Topics

 
• By Anabel Costa-Ferreira

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.

Global Pandemic Deal Adopted As 124 Countries Say Yes; US Sits Out

 
• By Neena Brizmohun

Now that the landmark Pandemic Agreement has finally been adopted, work will start on drafting a pathogen access and benefit sharing system that will be voluntary for use by drug companies.

Global Pharma Guidance Tracker - April 2025

 
• By Vibha Sharma and Anabel Costa-Ferreira

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

More from Pink Sheet

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.

Quotable: Top Experts On Policy Hot Topics

 
• By Anabel Costa-Ferreira

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.